Mechanical Cardiopulmonary Resuscitation During Treatment of Acute Respiratory Failure Through Extracorporeal Membrane Oxygenation.
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Armin N Flinspach, MD.
- Phone Number: 0049-6301-5868
- Email: armin.flinspach@kgu.de
Study Contact Backup
- Name: Hendrik J Booke
- Phone Number: 0049-6301-5868
- Email: j.booke@icloud.com
Study Locations
-
-
Hessen
-
Frankfurt, Hessen, Germany, 60590
- University Hospital Frankfurt
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
Patients treated with veno-venous extracorporeal membrane oxygenation (vv-ECMO) due to respiratory failure during acute respiratory distress syndrome (ARDS).
Exclusion Criteria:
Patients treated with veno-arterial extracorporeal membrane oxygenation (va-ECMO)
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Retrospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
cardiopulmonary resuscitation during treatment with extracorporeal membrane oxygenation
Patients treated with venovenous extracorporeal membrane oxygenation (vv-ECMO) for acute respiratory distress syndrome (ARDS) during the retrospective observation period who required mechanical cardiovascular resuscitation (CPR) during their treatment.
|
|
Treatment with extracorporeal membrane oxygenation without resuscitation
Patients treated with venovenous extracorporeal membrane oxygenation (vv-ECMO) for acute respiratory distress syndrome (ARDS) without the need for cardiovascular resuscitation during the retrospective observation period.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Survival of mechanical cardiovascular resuscitation
Time Frame: During the intensive care stay ( usually between 2 and 8 weeks)
|
Survival of mechanical cardiovascular resuscitation
|
During the intensive care stay ( usually between 2 and 8 weeks)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Incidence of cardiovascular resuscitation i
Time Frame: During the observation period 2019-2022
|
Incidence of cardiovascular resuscitation in patients treated with venovenous extracorporeal membrane oxygenation.
|
During the observation period 2019-2022
|
|
Complications of resuscitation treatments
Time Frame: During the intensive care stay ( usually between 2 and 8 weeks)
|
Complications of cardiovascular resuscitation in patients treated with venovenous extracorporeal membrane oxygenation
|
During the intensive care stay ( usually between 2 and 8 weeks)
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CPR during VV-ECMO
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.